Patients with moderate-to-severe Acne Vulgaris 1726-nm laser, Acne Vulgaris
Conditions
Interventions
Patients were treated with 1726 nm Laser System with infrared camera for real-time epidermal temperature monitoring 4 sessions every 4 weeks.
Then they were instructed to follow up at 1, 3, 6,9 and 1
Experimental Device
1726 nm Laser System with infrared camera for real-time epidermal temperature monitoring
Sponsors
Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Male or female, age 18 years old or older 2. Have moderate-to-severe acne 3. Have acene vulgaris which not improved after using topical or oral antibiotics for 3 months 4. Not received any treatments of acne vulgaris within 1 month before the study
Exclusion criteria
Exclusion criteria: 1. Patients who are pregnant, lactating, and postpartum within 1 year 2. Patients with history of Cushing syndrome or Ehlers-Danlos syndrome 3. Patients with other skin diseases, or having infection at the area of face 4. Immunocompromised patients 5. Patients with hypertrophic scar or keloid 6. Patients with photosensitivity disorder 7. Patients with cancers or skin cancers 8. Patients with mental disorders 9. Received chemical peeling treatment within the last 1 month before participating in the study 10. Patients who taking oral isotretinoin within 12 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| inflammatory acne lesion count baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3, 6, 9and 12 months after 3rd treatment, physician, Investigator Global Assessment (IGA) baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3, 6, 9and 12 months after 3rd treatment, physician, sebum level baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3, 6, 9and 12 months after 3rd treatment, sebumeter | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3, 6, 9and 12 months after 3rd treatment, Adverse event, Physician improvement scale baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3, 6, 9and 12 months after 3rd treatment, physician,Patient improvement scale baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3, 6, 9and 12 months after 3rd treatment, Participants | — |
Countries
Thailand
Contacts
Public ContactWoraphong Manuskiatti
Department of Dermatology, Faculty of medicine Siriraj hospital, Mahidol university
Outcome results
None listed